Influenza Antiviral Use in Patients Hospitalized With Laboratory-Confirmed Influenza in the United States, FluSurv-NET, 2015–2019. (19th December 2022)

• Record Type: Journal Article
• Authors: Tenforde, Mark W; Cummings, Charisse N; O'Halloran, Alissa C; Rothrock, Gretchen; Kirley, Pam Daily; Alden, Nisha B; Meek, James; Yousey-Hindes, Kimberly; Openo, Kyle P; Anderson, Evan J; Monroe, Maya L; Kim, Sue; Nunez, Val Tellez; McMahon, Melissa; McMullen, Chelsea; Khanlian, Sarah A; Spina, Nancy L; Muse, Alison; Gaitán, Maria A; Felsen, Christina B; Lung, Krista; Shiltz, Eli; Sutton, Melissa; Thomas, Ann; Talbot, H Keipp; Schaffner, William; Price, Andrea; Chatelain, Ryan; Reed, Carrie; Garg, Shikha
• Is Part Of: Open forum infectious diseases. Volume 10:Number 1(2023)
• Publication Date: 2022-12-19
• Subjects: antiviral -- baloxavir -- hospital -- influenza -- oseltamivir -- treatment delay; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofac681
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: From surveillance data of patients hospitalized with laboratory-confirmed influenza in the United States during the 2015–2016 through 2018–2019 seasons, initiation of antiviral treatment increased from 86% to 94%, with increases seen across all age groups. However, 62% started therapy ≥3 days after illness onset, driven by late presentation to care.